tiprankstipranks
Amgen (HK:4332)
:4332
Hong Kong Market
4332
Amgen
RESEARCH TOOLSreports

Amgen (4332) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4332 Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
10 Buy
11 Hold
2 Sell
Based on 23 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4332 Stock 12 Month Forecast

Average Price Target

HK$3,106.76
―
Based on 23 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is HK$3,106.76 with a high forecast of HK$3,606.26 and a low forecast of HK$1,803.13. The average price target represents a 1725877.06% change from the last price of HK$0.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1665":"HK$1,665","2636":"HK$2,636","3607":"HK$3,607","2150.5":"HK$2,150.5","3121.5":"HK$3,121.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3606.2592124000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$3.61K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3106.758712794286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$3.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1803.1296062000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$1.80K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1665,2150.5,2636,3121.5,3607],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1741.251,1884.7131701846154,2028.1753403692308,2171.6375105538464,2315.0996807384618,2458.561850923077,2602.0240211076925,2745.486191292308,2888.9483614769233,3032.4105316615387,3175.872701846154,3319.3348720307695,3462.797042215385,{"y":3606.2592124000003,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1741.251,1846.2900548303296,1951.3291096606595,2056.3681644909893,2161.4072193213187,2266.4462741516486,2371.4853289819785,2476.524383812308,2581.5634386426377,2686.6024934729676,2791.641548303297,2896.6806031336264,3001.7196579639567,{"y":3106.758712794286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1741.251,1746.0108927846154,1750.7707855692308,1755.5306783538463,1760.2905711384615,1765.050463923077,1769.8103567076923,1774.5702494923078,1779.3301422769232,1784.0900350615386,1788.8499278461538,1793.6098206307693,1798.3697134153847,{"y":1803.1296062000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1666.776,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1684.565,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1684.565,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1684.565,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1702.479,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1702.479,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1702.479,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1721.741,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1721.741,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1721.741,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.251,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.251,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1741.251,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$3,606Average Price TargetHK$3,107Lowest Price TargetHK$1,803
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on HK:4332
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
08/28/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Amgen (NASDAQ: AMGN)
Scotiabank Analyst forecast on HK:4332
Louise Chen
Scotiabank
Scotiabank
HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/28/26
Amgen (AMGN) Gets a Buy from Scotiabank
TD Cowen Analyst forecast on HK:4332
Yaron Werber
TD Cowen
TD Cowen
HK$3,543.54
Buy
1968534.26%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and Amgen (NASDAQ: AMGN)
William Blair Analyst forecast on HK:4332
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on HK:4332
David Amsellem
Piper Sandler
Piper Sandler
HK$3,347.55→HK$3,582.74
Buy
1990311.18%
Upside
Reiterated
08/20/26
Amgen price target raised to $457 from $427 at Piper SandlerAmgen price target raised to $457 from $427 at Piper Sandler
Morgan Stanley Analyst forecast on HK:4332
Terence Flynn
Morgan Stanley
Morgan Stanley
HK$2,751.73→HK$2,837.97
Hold
1576549.56%
Upside
Reiterated
08/19/26
Amgen price target raised to $362 from $351 at Morgan StanleyAmgen price target raised to $362 from $351 at Morgan Stanley
Argus Research Analyst forecast on HK:4332
Jasper Hellweg
Argus Research
Argus Research
HK$3,606.26
Buy
2003377.34%
Upside
Assigned
08/18/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)
BMO Capital Analyst forecast on HK:4332
Evan Seigerman
BMO Capital
BMO Capital
HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/17/26
Amgen (AMGN) Receives a Buy from BMO Capital
Cantor Fitzgerald Analyst forecast on HK:4332
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
HK$2,743.89→HK$3,135.88
Hold
1742054.21%
Upside
Reiterated
08/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
Mizuho Securities Analyst forecast on HK:4332
Salim Syed
Mizuho Securities
Mizuho Securities
HK$2,375.43→HK$2,759.57
Hold
1532995.70%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)
Barclays Analyst forecast on HK:4332
Emily Field
Barclays
Barclays
HK$2,822.29→HK$2,979.08
Hold
1654946.50%
Upside
Reiterated
08/13/26
Barclays Reaffirms Their Hold Rating on Amgen (AMGN)
Citi Analyst forecast on HK:4332
Geoff Meacham
Citi
Citi
HK$2,704.69→HK$3,175.08
Hold
1763831.14%
Upside
Reiterated
08/10/26
Citi Keeps Their Hold Rating on Amgen (AMGN)
Guggenheim Analyst forecast on HK:4332
Vamil Divan
Guggenheim
Guggenheim
HK$2,689.02→HK$3,041.8
Hold
1689789.58%
Upside
Reiterated
08/07/26
Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim
J.P. Morgan Analyst forecast on HK:4332
Chris Schott
J.P. Morgan
J.P. Morgan
HK$2,743.89
Hold
1524284.93%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)
Oppenheimer Analyst forecast on HK:4332
Jay Olson
Oppenheimer
Oppenheimer
HK$3,135.88→HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/05/26
Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on HK:4332
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
08/28/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Amgen (NASDAQ: AMGN)
Scotiabank Analyst forecast on HK:4332
Louise Chen
Scotiabank
Scotiabank
HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/28/26
Amgen (AMGN) Gets a Buy from Scotiabank
TD Cowen Analyst forecast on HK:4332
Yaron Werber
TD Cowen
TD Cowen
HK$3,543.54
Buy
1968534.26%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and Amgen (NASDAQ: AMGN)
William Blair Analyst forecast on HK:4332
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on HK:4332
David Amsellem
Piper Sandler
Piper Sandler
HK$3,347.55→HK$3,582.74
Buy
1990311.18%
Upside
Reiterated
08/20/26
Amgen price target raised to $457 from $427 at Piper SandlerAmgen price target raised to $457 from $427 at Piper Sandler
Morgan Stanley Analyst forecast on HK:4332
Terence Flynn
Morgan Stanley
Morgan Stanley
HK$2,751.73→HK$2,837.97
Hold
1576549.56%
Upside
Reiterated
08/19/26
Amgen price target raised to $362 from $351 at Morgan StanleyAmgen price target raised to $362 from $351 at Morgan Stanley
Argus Research Analyst forecast on HK:4332
Jasper Hellweg
Argus Research
Argus Research
HK$3,606.26
Buy
2003377.34%
Upside
Assigned
08/18/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)
BMO Capital Analyst forecast on HK:4332
Evan Seigerman
BMO Capital
BMO Capital
HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/17/26
Amgen (AMGN) Receives a Buy from BMO Capital
Cantor Fitzgerald Analyst forecast on HK:4332
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
HK$2,743.89→HK$3,135.88
Hold
1742054.21%
Upside
Reiterated
08/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)
Mizuho Securities Analyst forecast on HK:4332
Salim Syed
Mizuho Securities
Mizuho Securities
HK$2,375.43→HK$2,759.57
Hold
1532995.70%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)
Barclays Analyst forecast on HK:4332
Emily Field
Barclays
Barclays
HK$2,822.29→HK$2,979.08
Hold
1654946.50%
Upside
Reiterated
08/13/26
Barclays Reaffirms Their Hold Rating on Amgen (AMGN)
Citi Analyst forecast on HK:4332
Geoff Meacham
Citi
Citi
HK$2,704.69→HK$3,175.08
Hold
1763831.14%
Upside
Reiterated
08/10/26
Citi Keeps Their Hold Rating on Amgen (AMGN)
Guggenheim Analyst forecast on HK:4332
Vamil Divan
Guggenheim
Guggenheim
HK$2,689.02→HK$3,041.8
Hold
1689789.58%
Upside
Reiterated
08/07/26
Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim
J.P. Morgan Analyst forecast on HK:4332
Chris Schott
J.P. Morgan
J.P. Morgan
HK$2,743.89
Hold
1524284.93%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)
Oppenheimer Analyst forecast on HK:4332
Jay Olson
Oppenheimer
Oppenheimer
HK$3,135.88→HK$3,527.86
Buy
1959823.49%
Upside
Reiterated
08/05/26
Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months
David AmsellemPiper Sandler
Success Rate
14/19 ratings generated profit
74%
Average Return
+6.93%
Copying David Amsellem's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +6.93% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
19/19 ratings generated profit
100%
Average Return
+30.29%
Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.29% per trade.
2 Years
David AmsellemPiper Sandler
Success Rate
19/19 ratings generated profit
100%
Average Return
+43.04%
Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4332 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
25
25
26
19
24
Hold
25
27
27
22
26
Sell
1
2
2
2
3
Strong Sell
0
0
0
0
0
total
51
54
55
43
53
In the current month, 4332 has received 24 Buy Ratings, 26 Hold Ratings, and 3 Sell Ratings. 4332 average Analyst price target in the past 3 months is 3,106.76.
Each month's total comprises the sum of three months' worth of ratings.

4332 Financial Forecast

4332 Earnings Forecast

Next quarter’s earnings estimate for 4332 is HK$45.36 with a range of HK$42.96 to HK$48.33. The previous quarter’s EPS was HK$49.31. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4332 is HK$45.36 with a range of HK$42.96 to HK$48.33. The previous quarter’s EPS was HK$49.31. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Sales Forecast

Next quarter’s sales forecast for 4332 is HK$78.76B with a range of HK$77.20B to HK$80.55B. The previous quarter’s sales results were HK$78.93B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4332 is HK$78.76B with a range of HK$77.20B to HK$80.55B. The previous quarter’s sales results were HK$78.93B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4332 has Performed in-line its overall industry.

4332 Stock Forecast FAQ

What is HK:4332’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is 3,106.76.
    What is HK:4332’s upside potential, based on the analysts’ average price target?
    Amgen has 1725877.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Amgen a Buy, Sell or Hold?
          Amgen has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 11 hold ratings and 2 sell ratings.
            What is Amgen’s share price target?
            The average share price target for Amgen is 3,106.76. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$3,606.26 ,and the lowest forecast is HK$1,803.13. The average share price target represents 1725877.06% Increase from the current price of HK$0.18.
              What do analysts say about Amgen?
              Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of Amgen?
                To buy shares of HK:4332, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.